$584 Million is the total value of Ally Bridge Group (NY) LLC's 30 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | SPDR SER TRput | $154,858,000 | – | 1,100,000 | +100.0% | 26.54% | – | |
| MDVL | New | MEDAVAIL HOLDINGS INC | $43,958,000 | – | 2,920,780 | +100.0% | 7.53% | – |
| AVIR | New | ATEA PHARMACEUTICALS INC | $42,477,000 | – | 1,016,688 | +100.0% | 7.28% | – |
| New | SAREPTA THERAPEUTICS INCcall | $40,679,000 | – | 238,600 | +100.0% | 6.97% | – | |
| CERE | New | CEREVEL THERAPEUTICS HLDNG I | $29,304,000 | – | 1,767,440 | +100.0% | 5.02% | – |
| SYRS | New | SYROS PHARMACEUTICALS INC | $28,671,000 | – | 2,642,500 | +100.0% | 4.91% | – |
| FATE | New | FATE THERAPEUTICS INC | $23,642,000 | – | 260,000 | +100.0% | 4.05% | – |
| NTRA | New | NATERA INC | $18,710,000 | – | 188,000 | +100.0% | 3.21% | – |
| COGT | New | COGENT BIOSCIENCES INC | $18,222,000 | – | 1,622,591 | +100.0% | 3.12% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $16,704,000 | – | 360,000 | +100.0% | 2.86% | – |
| RGEN | New | REPLIGEN CORP | $15,809,000 | – | 82,500 | +100.0% | 2.71% | – |
| CSTL | New | CASTLE BIOSCIENCES INC | $14,102,000 | – | 210,000 | +100.0% | 2.42% | – |
| ORIC | New | ORIC PHARMACEUTICALS INC | $13,982,000 | – | 413,061 | +100.0% | 2.40% | – |
| LUNG | New | PULMONX CORP | $13,743,000 | – | 199,122 | +100.0% | 2.36% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $13,156,000 | – | 230,000 | +100.0% | 2.26% | – |
| NTLA | New | INTELLIA THERAPEUTICS INC | $12,240,000 | – | 225,000 | +100.0% | 2.10% | – |
| AUPH | New | AURINIA PHARMACEUTICALS INC | $11,867,000 | – | 858,032 | +100.0% | 2.03% | – |
| ITOS | New | ITEOS THERAPEUTICS INC | $10,917,000 | – | 322,794 | +100.0% | 1.87% | – |
| ITMR | New | ITAMAR MED LTDsponsored ads | $9,969,000 | – | 501,964 | +100.0% | 1.71% | – |
| ARVN | New | ARVINAS INC | $8,493,000 | – | 100,000 | +100.0% | 1.46% | – |
| FRLN | New | FREELINE THERAPEUTICS HLDGSsponsored ads | $7,761,000 | – | 425,000 | +100.0% | 1.33% | – |
| VIR | New | VIR BIOTECHNOLOGY INC | $7,365,000 | – | 275,000 | +100.0% | 1.26% | – |
| FDMT | New | 4D MOLECULAR THERAPEUTICS IN | $6,218,000 | – | 150,000 | +100.0% | 1.07% | – |
| New | APTOSE BIOSCIENCES INC | $6,172,000 | – | 1,409,150 | +100.0% | 1.06% | – | |
| SBTX | New | SILVERBACK THERAPEUTICS INC | $5,958,000 | – | 128,572 | +100.0% | 1.02% | – |
| KDNY | New | CHINOOK THERAPEUTICS INC | $3,166,000 | – | 199,600 | +100.0% | 0.54% | – |
| ORTX | New | ORCHARD THERAPEUTICS PLCads | $2,365,000 | – | 547,427 | +100.0% | 0.40% | – |
| ONCT | New | ONCTERNAL THERAPEUTICS INC | $1,470,000 | – | 300,000 | +100.0% | 0.25% | – |
| EPIX | New | ESSA PHARMA INC | $933,000 | – | 78,185 | +100.0% | 0.16% | – |
| NSTG | New | NANOSTRING TECHNOLOGIES INC | $620,000 | – | 9,277 | +100.0% | 0.11% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 11 | Q2 2023 | 8.9% |
| UNUM THERAPEUTICS INC | 8 | Q3 2022 | 7.3% |
| RAPID MICRO BIOSYSTEMS INC-A | 8 | Q2 2023 | 3.5% |
| FATE THERAPEUTICS INC | 7 | Q2 2022 | 5.8% |
| VIRIDIAN THERAPEUTICS INC | 7 | Q2 2023 | 6.8% |
| SYROS PHARMACEUTICALS INC | 7 | Q2 2022 | 4.9% |
| REPLIGEN CORP | 7 | Q4 2022 | 6.5% |
| NAUTILUS BIOTECHNOLOGY INC | 7 | Q4 2022 | 3.8% |
| ARVINAS INC | 6 | Q1 2022 | 7.5% |
| NUVATION BIO INC | 6 | Q2 2022 | 4.9% |
View Ally Bridge Group (NY) LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | November 19, 2020 | 1,420,500 | 8.0% |
View Ally Bridge Group (NY) LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Ally Bridge Group (NY) LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.